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COMMENTARY
Involve Children and Parents in Clinical Studies
Eric Vermeulen1,*, Kim Karsenberg1, Johanna H. van der Lee2,3 and Saskia N. de Wildt4,5
There is a need for more and good pediatric research because 
many treatments are still not evidence based. Pediatric stud-
ies often fail so guidance for pediatric drug research, as given 
by Shakhnovich et al.,1 is very welcome. This commentary ar-
gues for an addition to their advice: involve children and par-
ents in the (design of) clinical studies. There is evidence that 
patient involvement enhances research, also in pediatrics.
In their important paper, Shakhnovich et al.1 describe the 
essential elements of pediatric drug research, discussing 
current guidelines and literature concerning pediatric clinical 
research. A possible addition to their advice to improve clin-
ical research in pediatrics could be to involve children and 
parents in the design of the clinical study. We hope that by 
adding some of the literature about experiences and policies 
we can help improve pediatric clinical research even more.
The involvement of (adult) patients has been shown to pre-
vent research waste and to improve inclusion/retention rates 
and, therefore, to prevent failed clinical trials.2 Involvement, 
therefore, also reduces costs.2 The need to involve children/
parents in research design, the preparation of patients’ doc-
umentation, and information materials to improve research 
protocols and enhance research participation is widely ac-
knowledged.3 The failure of almost one in five pediatric tri-
als, mainly due to recruitment problems, as referred to by 
Shakhnovich et al.1 (Pica and Bourgeois),4 might have been 
at least partly prevented by engaging/involving parents and 
children in the design stage. Early involvement of patients 
in the trial design may result in identification of trial aspects 
that are less acceptable or unclear for potential participants. 
Adaptation of these aspects may enhance the willingness to 
participate in the trial.5 There is evidence that recruitment in-
creases with patient engagement, and that patient engage-
ment enhances the quality of research (e.g., by the choice 
of relevant outcome measures).2 Patient involvement should 
be seen as an integral part of designing a study.6
The need to involve children/parents in research design, 
the preparation of patients’ documentation, and information 
materials to improve research protocols and enhance re-
search participation is widely acknowledged. The US Food 
and Drug Administration (FDA) wants to integrate the pa-
tient’s perspective in drug development, a policy described 
in Mullin et al.7 There are many examples of involvement of 
children and parents in research.8 Patient engagement is, for 
example, arranged via members of the Children’s Advisory 
Network and Young Persons Advisory Groups (YPAGs)9 with 
specific tools for involvement.10
In the United States, engagement (in general, not specific for 
pediatrics) is attained and promoted in (for example) Patient-
Centered Outcomes Research Institute (PCORI) in Boston (https 
://www.pcori.org/about-us/our-progr ams/engag ement/ pub-
lic-and-patie nt-engag ement/ engag ement-resou rces#conte nt-
4029). In Canada, patient engagement in research (in general) 
is promoted via Strategy for Patient-Oriented Research (SPOR; 
(http://www.cihr-irsc.gc.ca/e/41204.html)) and (http://www.
cihr-irsc.gc.ca/e/45851.html). Great Britain has, as part of the 
National Institutes of Health Research, the institute INVOLVE with 
guidance, resources, and literature about patient engagement 
in general and specifically for children (https ://www.invo.org.
uk/curre nt-work/invol ving-child ren-and-young-peopl e/), which 
also shows further literature on the matter (https ://www.invo.
org.uk/curre nt-work/invol ving-child ren-and-young-peopl e/ 
refer ences-on-invol ving-child ren-and-young-people-in- 
resea rch/). In Europe, guidance for patient involvement in pedi-
atrics is given through the project RESPECT (https ://issuu.com/
respe ct_patie nt_needs/ docs/respe ct_book?viewM ode=doubl 
ePage ). Further, in Europe, there are research networks that 
integrate patient engagement in research: European Paediatric 
Translational Research Infrastructure (EPTRI; (https ://eptri.eu/)), 
Paediatric Clinical Research Infrastructure Network (PedCRIN; 
(https ://www.ecrin.org/proje cts/pedcrin)), and Conect 4 chil-
dren (C4C; Collaborative Network for European Clinical Trials 
for Children (https ://conec t4chi ldren.org/)).
As an example, in PedCRIN, the (potential) role of children 
and/or parents is identified through consultations of YPAGs 
and patient groups by means of a focus group; a group 
meeting in which clinical studies that are supported by 
PedCRIN (https ://www.ecrin.org/proje cts/pedcr in/call-out-
come) are discussed. During a focus group, children and/or 
parents are informed about a certain topic and they can give 
their views, with the idea that participants learn from each 
other and that, therefore, more diverse responses are gener-
ated. PedCRIN has developed a concise meeting guide for 
consulting parents and children that is available on request 
from the authors, as well as more literature about the topic.
One of the PedCRIN-deliverables deals with pediatric pa-
tient involvement in research (https ://www.ecrin.org/sites/ 
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defau lt/files/ PedCR IN/PedCR IN%20Del ivera bles/WP5%20
D5.13%20Pat ient%20eng ageme nt%20and %20per spect 
ive%20int egrat ion%20.pdf) and provides more guidance and 
literature concerning the following topics.
POSSIBLE METHODS TO RETRIEVE INFORMATION
Interviews
Interviews are a suitable way to explore the child’s perspec-
tive. In general, it can be concluded that interviewing of chil-
dren poses extra demands on the structure of the interview, 
open-ended questions may not be suitable for all children, 
and special attention should be given not to pose leading 
questions. The presence of parents is to be decided upon, 
their presence may be necessary when interviewing young 
children, but they also interfere with the personal perspective 
of the child when they want to aid the answering of children.
Questionnaires
Children and parents can be asked to complete question-
naires. Well-designed questionnaires can be used by in-
vestigators to write the research protocol according to the 
wishes children and their parents/carers.
Focus groups
Focus groups are another possibility to retrieve informa-
tion from patients/parents/patient representatives. Focus 
groups, in general, do not have to be “face-to-face,” they 
can also be organized via the internet; “online focus groups.”
Consultation through a platform discussion
Patient organizations often organize platforms (e.g., via 
Facebook). Via such a platform, members can be asked to 
respond to a question or topic and views on the question 
or topic can be discussed among the members. The entries 
(texts) can be analyzed by researchers. The advantages are 
that participants do not need to travel and can respond at 
a time they choose.
Interviews and focus groups imply a “one time consul-
tation” in which the patient opinion is explored and deter-
mined. However, patient involvement should be a process, 
with continuity over the whole clinical research, not a one-off 
meeting or even several one-off meetings for every research 
phase. It is important to create a partnership environment to 
secure communication between the investigator team and 
the child and parents/carers.
Methods to engage in the design, execution, and 
communication regarding clinical trials
These phases consist of the design, conduct, and report 
phase.
During the design phase of the study
Possible designs. When a trial is being designed, different 
designs exist to choose from. Patients might have good 
arguments to prefer a specific type of design, or refute 
(another) one.
Choice of control arm (comparator). For patients, the 
type of comparator that is used in a trial, in general, is very 
important. Parents may be afraid that their children would 
be placed in the group with ineffective treatment. Therefore, 
parents or children should be involved in this decision-making 
process to understand the reasons for choosing a specific 
control arm, and to share their ideas on possible alternatives.
Outcome measures. The choice of outcome measures 
is also a topic that patients would like to have influence 
on. That patient involvement in research leads to better 
outcome measures for research has been demonstrated. 
The FDA acknowledges the importance of determining the 
patient perspectives by means of PROMs, as described in 
the study of Mullin et al.7
During the conduct of study
Informed consent. Children need age-specific and 
experience-specific information. Children’s participation 
in designing the documents can improve the subsequent 
comprehension and assent.
A continual dialogue needs to be established that gives 
children and parents the opportunity to exchange informa-
tion. This can be done by an ongoing evaluation of patient 
(parent) experiences by means of a small questionnaire. 
Children and parents indicate that they wish to be asked 
about their experiences during the clinical trial. A continual 
dialogue needs to be established that gives children and 
parents the opportunity to exchange information.
Report of study. Study participants often expect to be 
informed about the results of the study.
It should be explored how patients can be involved in the 
communication process regarding study results. It might be, 
depending on study design and/or type of disease studied, 
at what point in time patients want to be informed and about 
which results on which they want to receive information, 
and from whom. Involvement should explore how this can 
be done. An extended communication procedure providing 
patients and their families with study results is crucial. Lay 
summaries are part of that.
In conclusion, pediatric drug research should not be the 
sole domain of professionals, but should also include patients 
and parents as stakeholders along the drug development 
continuum. Patient associations can and do play an important 
role in initiating and supporting patient involvement, as was 
shown by, for example, the study by EURORDIS-Rare Diseases 
Europe, an alliance of rare disease patient organizations (https 
://www.ncbi.nlm.nih.gov/pmc/artic les/PMC35 31929/ pdf/
msy-0003-0237.pdf). The European Patients Forum shows 
the value of patient organizations (in research) (http://www.
eu-patie nt.eu/globa lasse ts/libra ry/publi catio ns/epf_added_
value_report_final.pdf). There is guidance for patient involve-
ment in pediatric research available and professionals could 
consider whether the study would profit from “one-time in-
volvement” by a consultation or rather attempt to keep pa-
tients (representatives) involved during the whole research 
process.
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